www.dailyrx.com - Clinical Trials News

Merck Provides Update on Investigational Drug for Insomnia

Staff — Mon, 06 Feb 2012 20:49:27 +0000

Merck, known as MSD outside the United States and Canada, provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia.

New Blood Clot Device 40% More Effective

Deanna Morey — Sun, 05 Feb 2012 22:34:05 +0000

An experimental device designed to remove blood clots from blocked vessels after a stroke has successfully outperformed a mechanical U.S. Food and Drug Administration-approved device during a trial.

Morning-After Pill Helps Control Uterine Tumors

Tara Haelle — Sat, 04 Feb 2012 11:10:05 +0000

An emergency birth control pill taken after intercourse to prevent pregnancy has been found to prevent something else: intense bleeding caused by fibroids.

Arrhythmia Drug Boasts Lower Brain Bleeding

Deanna Morey — Thu, 02 Feb 2012 23:40:54 +0000

Prior to its approval last year, there was much debate about Xarelto (rivaroxaban), an anti-clotting drug designed to prevent stroke among patients with atrial fibrillation, a common heart arrhythmia.

Antipsychotic Drugs May Cause Metabolic Problems

Christopher Wright — Thu, 02 Feb 2012 22:05:00 +0000

Antipsychotic drugs are among the most prescribed drugs in the U.S. Almost all of these drugs are known to possibly cause obesity and diabetes, and, until recently, nobody knew why.

Childhood Infections Linked to Stroke Risk

Deanna Morey — Wed, 01 Feb 2012 17:50:05 +0000

Minor infections during childhood could have more devastating consequences. Common infections could put kids at a higher risk of stroke during the initial month following an infection.

FDA Approves Gleevec for Rare Gastrointestinal Cancer

Staff — Wed, 01 Feb 2012 15:09:34 +0000

The U.S. Food and Drug Administration granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.

Extending Lives of Men With Prostate Cancer

Laurie Stoneham — Tue, 31 Jan 2012 22:17:22 +0000

Usually, drug companies are the organizations that discover new medicines. It's rare for drugs to come out of academic labs, but that's just what happened with the first medication found to be effective against advanced prostate cancer.

FDA Approved New Type 2 Diabetes Drug

Staff — Tue, 31 Jan 2012 19:50:41 +0000

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

Restraining Brain Cancer Resistance

Travis Giddings — Mon, 30 Jan 2012 20:45:05 +0000

All of the drugs used to treat glioblastoma, an aggressive form of brain cancer, tend to use the same method of attack on a highly resistant point. Traditionally this has not gone very well.

FDA Approves Advanced Basal Cell Cancer Drug

Staff — Mon, 30 Jan 2012 18:18:19 +0000

Roche announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

Tasigna Recommended for Second-Line CML

Laurie Stoneham — Mon, 30 Jan 2012 11:54:49 +0000

Tasigna (nilotinib) is one of the three major medications currently being used to treat chronic myeloid leukemia (CML). Now it has become a preferred drug in one country.

Fewer Hot Flashes, Naturally

Tara Haelle — Sun, 29 Jan 2012 16:30:11 +0000

A dietary supplement with a certain soy germ ingredient reduced the frequency of hot flashes in women experiencing menopause.

Chronic Lymphocytic Leukemia, B Gone

Travis Giddings — Sat, 28 Jan 2012 11:46:06 +0000

Typical cancer treatments involve broad spectrum drugs that can cause harmful effects to a wide range of cells. Until recently, specialized medicines without a long list of side effects were a rarity.

A New Safe and Effective COPD Treatment

Charles Poladian — Wed, 25 Jan 2012 19:17:46 +0000

There is no cure for chronic obstructive pulmonary disease (COPD) but there are new treatments. A new once daily treatment shows promise in improving lung function in COPD sufferers.

FDA Approves Subcutaneous Administration of Takeda Drug Velcade

Staff — Tue, 24 Jan 2012 22:48:10 +0000

The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Velcade (bortezomib).

Positive Affirmation Improves Hypertension

Deanna Morey — Tue, 24 Jan 2012 18:16:22 +0000

In most cases blood pressure can easily be controlled by drugs. The key is ensuring patients stick to their drug regimen. That may be as simple as positive affirmation and small, unexpected gifts.

Brain Cancer Research Could Lead to New Drugs

Travis Giddings — Tue, 24 Jan 2012 15:16:11 +0000

Science has come a long way in understanding what cancer is, but how exactly cells become cancerous in the first place isn't as well understood. Stopping or reversing this process is an important research goal, but there's still a long way to go.

Is Gilenya Safe to Treat MS?

Lindsay Patterson — Tue, 24 Jan 2012 14:38:55 +0000

American and European health agencies are investigating the role of Gilenya, the first approved pill for treating multiple sclerosis.

Novartis Drug Treats Cushing's Disease

Staff — Sat, 21 Jan 2012 17:46:31 +0000

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor (SOM230, pasireotide) for the treatment of Cushing's disease.

Esophageal Cancer Gene Discovered

Laurie Stoneham — Thu, 19 Jan 2012 17:02:05 +0000

New research opens the door for new therapies to treat one of the worst sorts of cancer. Finding a genetic cause for esophageal cancer offers tremendous new opportunities.

Bayer’s Metastatic Colorectal Cancer Drug Presented

Staff — Thu, 19 Jan 2012 14:05:42 +0000

Results from the Phase III CORRECT study will be presented as a late breaking abstract in an oral abstract session on January 21 at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI).

Alzheimer’s Drug Phase 3 Results Not Good

Staff — Wed, 18 Jan 2012 12:56:42 +0000

Medivation, Inc. and Pfizer Inc. announced results from the CONCERT trial, which is a Phase 3 trial that evaluated Dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.

Treating the Effects of Gout Treatment

Travis Hill — Tue, 17 Jan 2012 14:24:53 +0000

The side effects of certain drugs can make some gout patients quit treatment. Fortunately, there may be one drug that stops the painful flare-ups sometimes associated with gout treatment.

Herpes Hides From the Eye

Tara Haelle — Mon, 16 Jan 2012 15:11:07 +0000

Taking antiviral therapy medications - even at high dosages - is not sufficient to prevent the spread of genital herpes, even when symptoms are not present.

Hit Me With Your Best Shot

Tara Haelle — Sun, 15 Jan 2012 23:20:02 +0000

A vaccine to protect against herpes has shown some success for one strain of the virus, offering researchers hope that they're on the right path to a more comprehensive vaccine.

Closing the Heart Attack Gap

Deanna Morey — Fri, 13 Jan 2012 13:56:31 +0000

Heart attack care for Asian Americans has been lacking. In recent years a new report shows substantial improvements in care have helped level the playing field in ensuring Asians receive adequate care.

New Application for Bayer Heart Drug

Staff — Fri, 06 Jan 2012 22:11:47 +0000

Bayer’s cooperation partner, Janssen Research & Development, L.L.C. has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral anticoagulant Xarelto (rivaroxaban) in combination with standard antiplatelet therapy to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS).

Deadly Sepsis Mechanism Identified

Deanna Morey — Fri, 30 Dec 2011 20:14:10 +0000

When patients, often those who are hospitalized in grave condition, develop sepsis, the potentially deadly bloodstream infection causes massive cell death. Now scientists have pinpointed how that happens.

Avastin Useful in Treating Ovarian Cancer

Laurie Stoneham — Wed, 28 Dec 2011 22:08:19 +0000

The main goal in treating ovarian cancer is preventing or delaying it from getting worse. A drug that's been controversial in treating advanced breast cancer shows promise in treating ovarian cancer.